immunocore-logo-2018
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
June 01, 2024 08:00 ET | Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
immunocore-logo-2018
Immunocore announces upcoming presentation and posters at ASCO 2024
April 24, 2024 10:00 ET | Immunocore Holdings plc
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be...
immunocore-logo-2018
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
January 05, 2024 07:00 ET | Immunocore Holdings Limited
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation Increasing commercial access to KIMMTRAK (tebentafusp-tebn)...
immunocore-logo-2018
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
immunocore-logo-2018
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
October 21, 2023 08:45 ET | Immunocore Holdings Limited
Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01...
immunocore-logo-2018
Immunocore announces upcoming presentation and posters at ESMO 2023
October 06, 2023 07:01 ET | Immunocore Holdings Limited
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...
immunocore-logo-2018
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
August 03, 2023 08:00 ET | Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
immunocore-logo-2018
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
June 03, 2023 07:00 ET | Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
February 28, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
immunocore-logo-2018
Immunocore is awarded the Prix Galien France award for KIMMTRAK
December 15, 2022 06:00 ET | Immunocore Holdings Limited
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE,...